ConductScience.org, home

Paper25035124

Targeting cancer-derived adenosine: new therapeutic approaches.

Young A and 3 others. Cancer Discov, 2014. Cited by 273 papers, by iCite.

Cite this record

ConductScience Library. Targeting cancer-derived adenosine: new therapeutic approaches. Papers, record 25035124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25035124

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting cancer-derived adenosine: new therapeutic approaches.
PubMed
Journal
Cancer Discov
PubMed
Year
2014
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
273
iCite
Relative citation ratio, by iCite
6.82
iCite
Revised in PubMed
2021-01-03
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Young AArabella
2Mittal DDeepak
3Stagg JJohn
4Smyth MJMark J

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
5'-NucleotidaseMajor topic
AdenosineMajor topic
NeoplasmsMajor topic
Animals
Antigens, CD
Apyrase
GPI-Linked Proteins
Humans
Immunosuppressive Agents
Mice
Molecular Targeted Therapy
Purinergic P1 Receptor Antagonists

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Canadian Institutes of Health ResearchCanadaPubMed

Source PubMed

Download CSV of grants

Cited by190

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 273 citations.

PMIDTitleJournalYearIn PapersSource
42831935From danger to resolution: targeting purinergic signaling in CNS diseases.Med Chem Res2026https://conductscience.org/library/papers/42831935PubMed
42794815Novel Fluorophenylated Dihydroimidazotriazinones as Potential Anticancer Agents: Design, Synthesis, In Vitro, Ex Vivo and In Silico Characterisation.Int J Mol Sci2026https://conductscience.org/library/papers/42794815PubMed
42259773Engineering an AIEgen-based platform integrating CRISPR/Cas9 to remodel the tumor microenvironment and reinforce photo-immunotherapy against glioblastom.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42259773PubMed
42157841Discovery of Potent 1,3-Cyclobutane-Containing Dual A2A/A2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer.ACS Med Chem Lett2026https://conductscience.org/library/papers/42157841PubMed
41828851Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening.Molecules2026https://conductscience.org/library/papers/41828851PubMed
41767275USP5-mediated CD73 deubiquitination drives osimertinib resistance via PI3K/AKT and glycolysis activation in LUAD.iScience2026https://conductscience.org/library/papers/41767275PubMed
41573544Enzymatic and microenvironmental regulation in adenosine metabolism-mediated immunosuppression.Front Immunol2025https://conductscience.org/library/papers/41573544PubMed
41511395Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy.Clin Cancer Res2026https://conductscience.org/library/papers/41511395PubMed
40753303NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice.Cancer Gene Ther2025https://conductscience.org/library/papers/40753303PubMed
40677703Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.Front Immunol2025https://conductscience.org/library/papers/40677703PubMed
40649751Tumor-Associated Macrophage in Breast Tumor Microenvironment.Int J Mol Sci2025https://conductscience.org/library/papers/40649751PubMed
40530308Therapeutic potential of adenosine receptor modulators in cancer treatment.RSC Adv2025https://conductscience.org/library/papers/40530308PubMed
40447954Tumor hypoxia shapes natural killer cell anticancer activities.J Mol Med (Berl)2025https://conductscience.org/library/papers/40447954PubMed
40381484CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer.Transl Oncol2025https://conductscience.org/library/papers/40381484PubMed
40303336Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy.Theranostics2025https://conductscience.org/library/papers/40303336PubMed
40260303Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming.Front Oncol2025https://conductscience.org/library/papers/40260303PubMed
40229283MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer.Nat Commun2025https://conductscience.org/library/papers/40229283PubMed
40050505Enhancing immunotherapy with tumour-responsive nanomaterials.Nat Rev Clin Oncol2025https://conductscience.org/library/papers/40050505PubMed
40001572Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It.Biomolecules2025https://conductscience.org/library/papers/40001572PubMed
39996780The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas.Cells2025https://conductscience.org/library/papers/39996780PubMed

See all 190 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25035124

GET https://conductscience.org/api/papers/v1/25035124/cited_by?page=2